Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on (IMTX) Technical Data - news.stocktradersdaily.com

(IMTX) Technical Data  news.stocktradersdaily.com

(IMTX) Technical Data - news.stocktradersdaily.com

Click here to get full coverage on Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?  Yahoo Finance

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on Immatics Announces First Quarter 2025 Financial Results and Business Update - Stock Titan

Immatics Announces First Quarter 2025 Financial Results and Business Update  Stock Titan

Immatics Announces First Quarter 2025 Financial Results and Business Update - Stock Titan

Click here to get full coverage on Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq

Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation  Nasdaq

Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq

Click here to get full coverage on Immatics N.V. (NASDAQ:IMTX) Receives $14.67 Average PT from Brokerages - MarketBeat

Immatics N.V. (NASDAQ:IMTX) Receives $14.67 Average PT from Brokerages  MarketBeat

Immatics N.V. (NASDAQ:IMTX) Receives $14.67 Average PT from Brokerages - MarketBeat

Click here to get full coverage on We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - simplywall.st

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth  simplywall.st

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - simplywall.st

Click here to get full coverage on Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha

Immatics: Taking Off On A PRAME Rocketship  Seeking Alpha

Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha

Click here to get full coverage on Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire

Immatics Announces Upcoming Oral and Poster Presentation on  GlobeNewswire

Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire

Click here to get full coverage on Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds? - Insider Monkey

Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds?  Insider Monkey

Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds? - Insider Monkey

Click here to get full coverage on Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena - DirectorsTalk Interviews

Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena  DirectorsTalk Interviews

Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena - DirectorsTalk Interviews

Click here to get full coverage on Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan

Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025  Stock Titan

Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan

Click here to get full coverage on Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha

Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX)  Seeking Alpha

Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - simplywall.st

Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61%  simplywall.st

Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - simplywall.st

Click here to get full coverage on We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - Yahoo Finance

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely  Yahoo Finance

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - Yahoo Finance

Click here to get full coverage on Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha

Immatics: A Promising TCR Pipeline (NASDAQ:IMTX)  Seeking Alpha

Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update  GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Immatics Presents Promising IMA203 Data at ASCO 2025 - TipRanks

Immatics Presents Promising IMA203 Data at ASCO 2025  TipRanks

Immatics Presents Promising IMA203 Data at ASCO 2025 - TipRanks

Click here to get full coverage on Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM - TipRanks

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM  TipRanks

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM - TipRanks

Click here to get full coverage on Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire

Immatics Announces Proposed $150 Million Public Offering  GlobeNewswire

Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire

Click here to get full coverage on Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewswire

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME  GlobeNewswire

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewswire

Click here to get full coverage on Immatics rises on data from early stage cell therapy trial - Seeking Alpha

Immatics rises on data from early stage cell therapy trial  Seeking Alpha

Immatics rises on data from early stage cell therapy trial - Seeking Alpha

Click here to get full coverage on GatesAir to Showcase New Low-Power Transmission Products at IBC2024 - TVTechnology

GatesAir to Showcase New Low-Power Transmission Products at IBC2024  TVTechnology

GatesAir to Showcase New Low-Power Transmission Products at IBC2024 - TVTechnology

Click here to get full coverage on immatics n.v. announces upcoming annual general meeting - Investing.com

immatics n.v. announces upcoming annual general meeting  Investing.com

immatics n.v. announces upcoming annual general meeting - Investing.com

Click here to get full coverage on Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns - Yahoo Finance

Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns  Yahoo Finance

Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns - Yahoo Finance

Click here to get full coverage on IMTX Stock Price and Chart — NASDAQ:IMTX - TradingView

IMTX Stock Price and Chart — NASDAQ:IMTX  TradingView

IMTX Stock Price and Chart — NASDAQ:IMTX - TradingView

Click here to get full coverage on Immatics (IMTX) Stock Price, News & Analysis - MarketBeat

Immatics (IMTX) Stock Price, News & Analysis  MarketBeat

Immatics (IMTX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics - Stock Titan

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics  Stock Titan

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics - Stock Titan

Click here to get full coverage on Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year - Yahoo Finance

Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year  Yahoo Finance

Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year - Yahoo Finance

Click here to get full coverage on IMTX Stock: Why Immatics Shares Are Rocketing Higher Today - InvestorPlace

IMTX Stock: Why Immatics Shares Are Rocketing Higher Today  InvestorPlace

IMTX Stock: Why Immatics Shares Are Rocketing Higher Today - InvestorPlace

Click here to get full coverage on Immatics Announces Completion of Business Combination and Listing on NASDAQ - GlobeNewswire

Immatics Announces Completion of Business Combination and Listing on NASDAQ  GlobeNewswire

Immatics Announces Completion of Business Combination and Listing on NASDAQ - GlobeNewswire

Click here to get full coverage on Immatics (IMTX) Earnings Date and Reports 2025 - MarketBeat

Immatics (IMTX) Earnings Date and Reports 2025  MarketBeat

Immatics (IMTX) Earnings Date and Reports 2025 - MarketBeat

Click here to get full coverage on Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading - The Business Journals

Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading  The Business Journals

Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading - The Business Journals

Click here to get full coverage on Immatics Announces First Bristol Myers Squibb Opt-in of - GlobeNewswire

Immatics Announces First Bristol Myers Squibb Opt-in of  GlobeNewswire

Immatics Announces First Bristol Myers Squibb Opt-in of - GlobeNewswire

Click here to get full coverage on Ironman Recognizes IM Texas Times as World Records on Admittedly Shortened Course - Triathlete

Ironman Recognizes IM Texas Times as World Records on Admittedly Shortened Course  Triathlete

Ironman Recognizes IM Texas Times as World Records on Admittedly Shortened Course - Triathlete

Click here to get full coverage on Fundus biomicroscopy: Complete remission of the retinallesions was... - researchgate.net

Fundus biomicroscopy: Complete remission of the retinallesions was...  researchgate.net

Fundus biomicroscopy: Complete remission of the retinallesions was... - researchgate.net

Click here to get full coverage on No records recognized at Ironman Texas this year - Triathlon Magazine Canada

No records recognized at Ironman Texas this year  Triathlon Magazine Canada

No records recognized at Ironman Texas this year - Triathlon Magazine Canada

Click here to get full coverage on Exchange Traded Concepts LLC Has $115,000 Stake in Immatics N.V. (NASDAQ:IMTX) - Defense World

Exchange Traded Concepts LLC Has $115,000 Stake in Immatics N.V. (NASDAQ:IMTX)  Defense World

Exchange Traded Concepts LLC Has $115,000 Stake in Immatics N.V. (NASDAQ:IMTX) - Defense World

Click here to get full coverage on Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $14.67 - Defense World

Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $14.67  Defense World

Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $14.67 - Defense World

Click here to get full coverage on Immatics (NASDAQ:IMTX) Shares Sold by Two Sigma Advisers LP - Defense World

Immatics (NASDAQ:IMTX) Shares Sold by Two Sigma Advisers LP  Defense World

Immatics (NASDAQ:IMTX) Shares Sold by Two Sigma Advisers LP - Defense World

Click here to get full coverage on Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX) - Defense World

Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX)  Defense World

Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX) - Defense World

Click here to get full coverage on Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX) - Defense World

Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX)  Defense World

Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX) - Defense World

Click here to get full coverage on Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts - Defense World

Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts  Defense World

Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts - Defense World

Click here to get full coverage on Cantor Fitzgerald Comments on Immatics FY2026 Earnings - Defense World

Cantor Fitzgerald Comments on Immatics FY2026 Earnings  Defense World

Cantor Fitzgerald Comments on Immatics FY2026 Earnings - Defense World

POST

Immatics N.V. Ordinary Shares

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics NV (IMTX)

Price Chart

Key Statistics

Technicals

About IMTX

Latest News

(IMTX) Technical Data - news.stocktradersdaily.com

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance

Immatics Announces First Quarter 2025 Financial Results and Business Update - Stock Titan

Advanced Charts

Top Gainers

Top Losers